JP2010528663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528663A5 JP2010528663A5 JP2010511354A JP2010511354A JP2010528663A5 JP 2010528663 A5 JP2010528663 A5 JP 2010528663A5 JP 2010511354 A JP2010511354 A JP 2010511354A JP 2010511354 A JP2010511354 A JP 2010511354A JP 2010528663 A5 JP2010528663 A5 JP 2010528663A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- rtef
- item
- dominant negative
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035148 Transcriptional enhancer factor TEF-3 Human genes 0.000 claims description 45
- 101710152984 Transcriptional enhancer factor TEF-3 Proteins 0.000 claims description 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 44
- 229920001184 polypeptide Polymers 0.000 claims description 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 22
- 150000007523 nucleic acids Chemical group 0.000 claims description 21
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 12
- 208000002780 macular degeneration Diseases 0.000 claims description 9
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 6
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 108700024394 Exon Proteins 0.000 claims description 4
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 238000011319 anticancer therapy Methods 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims description 3
- 208000022211 Arteriovenous Malformations Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010011017 Corneal graft rejection Diseases 0.000 claims description 3
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 3
- 201000000054 Coronary Restenosis Diseases 0.000 claims description 3
- 206010056489 Coronary artery restenosis Diseases 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 101150021185 FGF gene Proteins 0.000 claims description 3
- 108091008794 FGF receptors Proteins 0.000 claims description 3
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010067807 Gingival cancer Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 108091008605 VEGF receptors Proteins 0.000 claims description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 3
- 230000002491 angiogenic effect Effects 0.000 claims description 3
- 230000005744 arteriovenous malformation Effects 0.000 claims description 3
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 201000006491 bone marrow cancer Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000000159 corneal neovascularization Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000024519 eye neoplasm Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 201000008106 ocular cancer Diseases 0.000 claims description 3
- 201000002575 ocular melanoma Diseases 0.000 claims description 3
- 229940005014 pegaptanib sodium Drugs 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 229960003876 ranibizumab Drugs 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 201000006134 tongue cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 2
- 101800000726 Mature small capsid protein Proteins 0.000 claims description 2
- 101800000874 Small capsid protein Proteins 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- 108010094020 polyglycine Proteins 0.000 claims description 2
- 108010087948 polymethionine Proteins 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000007910 systemic administration Methods 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 238000011122 anti-angiogenic therapy Methods 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 230000001939 inductive effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94224907P | 2007-06-06 | 2007-06-06 | |
| US60/942,249 | 2007-06-06 | ||
| PCT/US2008/066058 WO2008154351A1 (en) | 2007-06-06 | 2008-06-06 | Rtef-1 variants and the use thereof for inhibition of angiogenesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013154186A Division JP2013215210A (ja) | 2007-06-06 | 2013-07-25 | 血管形成の阻害のためのｒｔｅｆ−１変異体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010528663A JP2010528663A (ja) | 2010-08-26 |
| JP2010528663A5 true JP2010528663A5 (enExample) | 2012-06-14 |
| JP5410416B2 JP5410416B2 (ja) | 2014-02-05 |
Family
ID=39657274
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010511354A Expired - Fee Related JP5410416B2 (ja) | 2007-06-06 | 2008-06-06 | 血管形成の阻害のためのｒｔｅｆ−１変異体およびその使用 |
| JP2013154186A Withdrawn JP2013215210A (ja) | 2007-06-06 | 2013-07-25 | 血管形成の阻害のためのｒｔｅｆ−１変異体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013154186A Withdrawn JP2013215210A (ja) | 2007-06-06 | 2013-07-25 | 血管形成の阻害のためのｒｔｅｆ−１変異体およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8748379B2 (enExample) |
| EP (1) | EP2170938B1 (enExample) |
| JP (2) | JP5410416B2 (enExample) |
| CN (1) | CN101970472B (enExample) |
| AT (1) | ATE553771T1 (enExample) |
| AU (1) | AU2008261969B2 (enExample) |
| CA (1) | CA2689913C (enExample) |
| DK (1) | DK2170938T3 (enExample) |
| IL (1) | IL202338A (enExample) |
| WO (1) | WO2008154351A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| KR101553740B1 (ko) * | 2009-08-17 | 2015-09-17 | 트라콘 파마수티칼즈, 인코포레이티드 | 항엔도글린 항체 및 항ｖｅｇｆ 제제를 사용한 암 치료를 위한 병용 요법 |
| US8785385B2 (en) | 2010-04-19 | 2014-07-22 | Research Development Foundation | RTEF-1 variants and uses thereof |
| IT1405683B1 (it) * | 2010-10-18 | 2014-01-24 | Istituto Giannina Gaslini | Vettori lipidici veicolanti silenziatori genici |
| EP2825191B1 (en) | 2012-03-16 | 2019-08-28 | University Health Network | Soluble toso protein and its use in treating autoimmune disorders |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| CA2917077A1 (en) | 2013-07-03 | 2015-01-08 | University Health Network | Antibodies to toso |
| WO2015130783A1 (en) * | 2014-02-25 | 2015-09-03 | Research Development Foundation | Sty peptides for inhibition of angiogenesis |
| CA2966905A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| TWI843989B (zh) | 2021-02-19 | 2024-06-01 | 美商美威高能離子醫療系統公司 | 用於粒子治療系統之支架 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995020975A1 (en) | 1994-02-04 | 1995-08-10 | The Regents Of The University Of California | Tef-1 isoforms and uses thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| US7122181B2 (en) | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
| US7183388B2 (en) | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
| US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
| DK1412493T3 (da) | 2001-08-02 | 2012-01-09 | Inst Clayton De La Rech | Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer |
| WO2005034881A2 (en) * | 2003-10-10 | 2005-04-21 | Beth Israel Deaconess Medical Center | Methods and compositions for treating conditions involving abnormal angiogenesis |
| WO2005073384A2 (en) | 2004-01-28 | 2005-08-11 | Research Development Foundation | Human soluble neuropilin-1 primary polyadenylation signal and uses thereof |
| WO2006055689A2 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
-
2008
- 2008-06-06 EP EP08770291A patent/EP2170938B1/en not_active Not-in-force
- 2008-06-06 JP JP2010511354A patent/JP5410416B2/ja not_active Expired - Fee Related
- 2008-06-06 WO PCT/US2008/066058 patent/WO2008154351A1/en not_active Ceased
- 2008-06-06 DK DK08770291.6T patent/DK2170938T3/da active
- 2008-06-06 AT AT08770291T patent/ATE553771T1/de active
- 2008-06-06 CN CN2008801004835A patent/CN101970472B/zh not_active Expired - Fee Related
- 2008-06-06 CA CA2689913A patent/CA2689913C/en not_active Expired - Fee Related
- 2008-06-06 US US12/134,626 patent/US8748379B2/en not_active Expired - Fee Related
- 2008-06-06 AU AU2008261969A patent/AU2008261969B2/en not_active Ceased
-
2009
- 2009-11-25 IL IL202338A patent/IL202338A/en active IP Right Grant
-
2013
- 2013-07-25 JP JP2013154186A patent/JP2013215210A/ja not_active Withdrawn
-
2014
- 2014-05-05 US US14/269,806 patent/US9512423B2/en not_active Expired - Fee Related
-
2016
- 2016-12-05 US US15/369,583 patent/US9937269B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010528663A5 (enExample) | ||
| ES3018262T3 (en) | Albumin binding domain fusion proteins | |
| ES2323468T3 (es) | Trampas de vegf y usos terapeuticos de las mismas. | |
| ES2827226T3 (es) | Diacuerpos monovalentes biespecíficos con capacidad de unión a gpA33 y CD3, y usos de los mismos | |
| US8507434B2 (en) | Peptide modulators of angiogenesis and use thereof | |
| ES2659764T3 (es) | Moléculas biespecíficas de unión a antígeno activadoras de linfocitos T | |
| ES2336832T3 (es) | Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr. | |
| BR112020004389A2 (pt) | composição, e, método para tratar ou prevenir uma doença ou distúrbio em um indivíduo em necessidade do mesmo. | |
| JP2021500071A (ja) | ヒト翻訳後修飾ｖｅｇｆ−ｔｒａｐによる眼疾患および転移性大腸がんの処置 | |
| ES2930681T3 (es) | Linfocitos T transfectados y receptores de linfocito T para el uso en la inmunoterapia contra el cáncer | |
| JP7597398B2 (ja) | 組換え神経成長因子のための組成物及び方法 | |
| CN109810995B (zh) | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 | |
| EP2172484A2 (en) | Serum albumin binding proteins | |
| JP2017529059A5 (enExample) | ||
| Khare et al. | Targeted drug delivery systems for pancreatic cancer | |
| EP3395366B1 (en) | Drug design method, obtained drug and application thereof | |
| ES2852001T3 (es) | Conjugados de anticuerpo-ureasa para propósitos terapéuticos | |
| CA2898128A1 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| CN117467025B (zh) | 一种抗vegf和补体双功能融合蛋白及其应用 | |
| JP2022512541A (ja) | Ｐｄ－１系キメラタンパク質を含む併用療法 | |
| BR112021007469A2 (pt) | anticorpos biespecíficos direcionados a exossomo | |
| US20140349944A1 (en) | Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases | |
| KR101575194B1 (ko) | 인간 페리틴 유래 융합폴리펩티드 | |
| US9878016B2 (en) | IGFBP-3 derivatives and uses thereof | |
| CA2796601A1 (en) | Rtef-1 variants and uses thereof |